Perspective Therapeutics, Inc. filed a current report on August 10, 2026, announcing its financial results for the quarter ended June 30, 2026, and posting an updated corporate presentation.

Key Highlights

  • Reporting period: Financial results cover the quarter ended June 30, 2026.
  • Filing date: The current report was filed and signed on August 10, 2026.
  • Exchange listing: Common Stock ($0.001 par value) trades on NYSE American LLC under the symbol CATX.
  • Corporate presentation: An updated corporate presentation was posted and filed as Exhibit 99.2 on August 10, 2026.
  • Signatory: The report was signed by Joel Sendek, Chief Financial Officer of Perspective Therapeutics, Inc.
  • Incorporation status: The company is incorporated in Delaware and is not classified as an emerging growth company.

Perspective Therapeutics Discloses Q2 2026 Operating Results and Corporate Update

Perspective Therapeutics, Inc., a Delaware-incorporated company headquartered in Seattle, Washington, filed a current report under Item 2.02 (Results of Operations and Financial Condition) to announce its financial results for the second quarter ended June 30, 2026. According to the filing, the results were communicated through a press release issued on August 10, 2026, which is furnished as Exhibit 99.1. The filing notes that the information provided under Item 2.02, including Exhibit 99.1, "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Under Item 8.01 (Other Events), the company disclosed that it also posted an updated corporate presentation on August 10, 2026. That presentation was filed as Exhibit 99.2 and incorporated by reference into Item 8.01. The filing was signed on behalf of the registrant by Chief Financial Officer Joel Sendek. Perspective Therapeutics lists its common stock, with a par value of $0.001 per share, on NYSE American LLC under the ticker symbol CATX.

What Was Disclosed

Perspective Therapeutics filed a current report on August 10, 2026, covering its Q2 2026 financial results via a furnished press release and an updated corporate presentation filed as separate exhibits. Chief Financial Officer Joel Sendek signed the filing on behalf of the company.